Raanan Berger

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

Tanguy Y. Seiwert, Barbara Burtness, Ranee Mehra et al. · The Lancet Oncology · 2016 · 1.7K citations

Medicine, Oncology, Pharmacotherapy +13

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Rita Nanda, Laura Q.M. Chow, Elizabeth Claire Dees et al. · Journal of Clinical Oncology · 2016 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

Pradip K. Majumder, Phillip G. Febbo, Rachel Bikoff et al. · Nature Medicine · 2004 · 956 citations

Medicine, Oncology, Urology +15

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta et al. · Journal of Clinical Oncology · 2016 · 859 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

Raanan Berger, Rinat Rotem‐Yehudar, Gideon Slama et al. · Clinical Cancer Research · 2008 · 692 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacokinetics +17